Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 159

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Hepatitis C virus dynamics in vivo : Effect of ribavirin and interferon alfa on viral turnover

Open access
Zeuzem, Stefan, Schmidt, Jürgen M., Lee, Jung-hun, von Wagner, Michael, Teuber, Gerlinde, Roth, Kurt W. · 1998 · Hepatology

Abstract

Treatment of patients with chronic hepatitis C with recombinant interferon alfa (rIFN-α) can cause a decrease of serum transaminases and hepatitis C virus (HCV) RNA. Recent trials evaluating combination therapy of IFN-α and ribavirin suggested a potential synergistic effect. From serial measurements of serum HCV RNA concentrations following treatment-induced perturbation of the balance between virus production and clearance, we compared the antiviral efficacy of both IFN-α alone and IFN-α in combination with ribavirin. Chronically HCV-infected patients were treated with either 3 × 3 MU or 3 × 6 MU rIFN-α per week or 3 × 6 MU rIFN-α plus 14 mg/kg of body weight ribavirin per day. The time-dependent HCV RNA concentrations during antiviral treatment were analyzed by iterative least-squares regression. After initiation of antiviral therapy, HCV RNA declined exponentially below the detection limit of the reverse-transcription polymerase chain reaction assay (1,000 HCV RNA molecules per milliliter) in 10 of 26 (39%), 10 of 19 (53%), and 10 of 18 patients (56%) treated with 3 × 3 MU, 3 × 6 MU rIFN-α without and with ribavirin, respectively. Viral clearance from serum was faster in patients treated with 3 × 6 MU rIFN-α (t1/2= 0.23 ± 0.15) compared with patients treated with 3 × 3 MU rIFN-α per week (0.67 ± 0.36 days) (P< .004). However, half-lives of viral clearance were similar in patients treated with rIFN-α or rIFN-α plus ribavirin. For virus release from infected hepatocytes, absence and presence of ribavirin yielded half-lives of t1/2= 2.54 ± 2.10 and t1/2= 1.99 ± 1.70, respectively, indicating that ribavirin does not significantly inhibit HCV production. In conclusion, the data of the present study indicate that higher rIFN-α doses accelerate viral clearance from serum. Ribavirin (14 mg/kg/d), however, lacks synergistic antiviral effects in the treatment of chronic hepatitis C with 3 × 6 MU rIFN-α per week.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.510280132

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 159

Metadata

Authors
Zeuzem, S., Schmidt, J. M., Lee, J.-H., von Wagner, M., Teuber, G., & Roth, K. W.
Venue
Hepatology
Published
1998-07
Volume
28
Issue
1
Pages
245-252
ISSN
0270-9139 (ISSN-L)
OpenAlex
W1981095040
Cited by
159
References
1
FWCI
14.46
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hepatitis C virus dynamics in vivo : Effect of ribavirin and interferon alfa on viral turnover. https://app.cochat.ai/papers/10.1002/hep.510280132
The paper
Zeuzem, S., Schmidt, J. M., Lee, J.-H., von Wagner, M., Teuber, G., & Roth, K. W. (1998). Hepatitis C virus dynamics in vivo : Effect of ribavirin and interferon alfa on viral turnover. Hepatology. https://doi.org/10.1002/hep.510280132

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.